Targeting of phosphorylated tau at threonine 181 by a Qβ virus‐like particle vaccine is safe, highly immunogenic, and reduces disease severity in mice and rhesus macaques

• Published in: Alzheimer's & dementia Vol. 21; no. 3; pp. e70101 - n/a
• Main Authors: Maphis, Nicole M., Hulse, Jonathan, Peabody, Julianne, Dadras, Somayeh, Whelpley, Madelin J, Kandath, Manas, Wilson, Colin, Hobson, Sasha, Thompson, Jeff, Poolsup, Suttinee, Beckman, Danielle, Ott, Sean P, Watanabe, Jennifer W., Usachenko, Jodie L., Van Rompay, Koen K, Morrison, John, Selwyn, Reed, Rosenberg, Gary, Knoefel, Janice, Chackerian, Bryce, Bhaskar, Kiran
• Format: Journal Article
• Language: English
• Published: United States John Wiley and Sons Inc 01.03.2025
• Subjects: Alzheimer Disease - immunology; Alzheimer's disease; Animals; Brain - pathology; Disease Models, Animal; Female; hTau; Humans; immunotherapy; Macaca mulatta; Male; Mice; mild cognitive impairment; non‐human primates; Phosphorylation; PS19; pT181; rhesus macaques; tau; tau Proteins - immunology; tau Proteins - metabolism; tauopathies; Tauopathies - immunology; Threonine - immunology; vaccines; Vaccines, Virus-Like Particle - immunology; virus‐like particles; hTau; rhesus macaques; vaccines; virus‐like particles; immunotherapy; non‐human primates; pT181; tau; mild cognitive impairment; tauopathies; Alzheimer's disease; PS19

INTRODUCTION Pathological accumulation of tau (pTau) contributes to various tauopathies, including Alzheimer's disease (AD), and correlates with cognitive decline. A rapid surge in tau‐targeted approaches via anti‐sense oligonucleotides, active/passive immunotherapies suggests that targeting p‐...